Search Back New search Go to resultsDiseaseMain groupHematological Diseases, Non-MalignantProtocol groupHemolytic DiseasesDiseaseHemolytic Uremic Syndrome, atypicalSubgroupICD10D59.3MeSHAtypical Hemolytic Uremic SyndromeSequenceECUL900, aHUS, Ind. (PID2704) -|- ECUL1200, aHUS, Maint. (PID2706)RAVU2700, aHUS, ind. (PID2705) -|- RAVU3300, aHUS, maint. (PID2707)ChemotherapyChemo-substanceChemo-substanceChemo-substanceChemo-substanceNo. Substances RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionEculizumabRavulizumabSupportive substanceBalanced Crystalloid SolutionEculizumabRavulizumabSupportive substanceBalanced Crystalloid SolutionEculizumabRavulizumabSupportive substanceBalanced Crystalloid SolutionEculizumabRavulizumabNo. Substances2Protocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationFirst lineTherapy phaseInductionMaintenanceTherapy intentiondisease controlRisksDiarrheaDyspneaEdemaHeadacheHemorrhageHypertensionHypokalemiaInfectionsPneumoniaRenal FailureSeizuresVomiting only studiesPublicationAuthorLegendre CRondeau RDiseaseAtypisches hämolytisch-uramisches Syndrom, ErstlinieAtypisches hämolytisch-uramisches Syndrom, LDH >1,5-fach erhöhtOriginIntensive Care Nephrology and Transplantation Department, Assistance Publique, Hôpitaux de Paris, 311 Study GroupService de Transplantation Adultes, Université Paris Descartes and Hôpital Necker, ParisProtocols in Revision 4 protocols foundProtocols under revision.Eculizumab 1200 Hemolytic Uremic Syndrome, atypical, maintenance (PID2706 V1.0)Eculizumab 900, Hemolytic Uremic Syndrome, atypical, induction (PID2704 V1.0)Ravulizumab 2700, Hemolytic Uremic Syndrome, atypical, induction (PID2705 V1.0)Ravulizumab 3300, Hemolytic Uremic Syndrome, atypical, maintenance (PID2707 V1.0)
